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CorrespondenceLETTERS TO THE EDITORCatheter-Based Renal Denervation in
ADPKD: Just for Pain Control?
To the Editor:
We read with interest the case report by Casteleijn et al,1 which
reported successful use of catheter-based renal denervation to
reduce chronic kidney pain in a patient with autosomal dominant
polycystic kidney disease (ADPKD). There have been several
published cases of renal denervation to provide pain relief for
patients with ADPKD (eg, Walsh and Sarria2), but none has
highlighted the positive effect of this procedure on blood pressure
(BP). Sympathetic overactivity plays a crucial pathogenetic role
in hypertension of ADPKD,3 and fewer than 30% of patients
undergoing treatment for the disease achieve BPs less than 130/
80 mm Hg.
Recently, we described an exceptional case of renal denervation
in a woman with single-kidney stage 4 chronic kidney disease
secondary to ADPKD and uncontrolled treatment-resistant hy-
pertension.4 Due to failure of all other therapeutic strategies,
including uninephrectomy, renal denervation by radiofrequency
ablation of the single renal artery was performed. After the pro-
cedure, the patient’s BP declined remarkably, decreasing her need
for antihypertensive medication. Moreover, the patient did not
experience a signiﬁcant decline in kidney function.
Several studies support the safety and efﬁcacy of renal dener-
vation.5,6 However, the existing evidence is limited by small
studies and short follow-up. A large trial,7 recently completed but
not yet published (at the time of writing), as well as ongoing
clinical trials,8-14 should provide important information regarding
the safety and efﬁcacy of renal denervation for resistant hyper-
tension or other indications.
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The letter by Riccio et al1 deals with a timely topic, adding
catheter-based renal denervation as a potential therapeutic option
for resistant hypertension in patients with autosomal dominant
polycystic kidney disease (ADPKD).
The uncontrolled small-scale Symplicity HTN-1 and HTN-2
trials suggested that renal denervation could be a promising
novel treatment for resistant hypertension in patients without
ADPKD.2,3 Unfortunately, the larger more recent Simplicity HTN-
3 trial showed that on 6-month follow-up, 364 patients treated with
renal denervation experienced no signiﬁcant reduction in blood
pressure compared with 171 control patients who underwent a
sham procedure.4 Although these novel data may eliminate renal
denervation as a treatment option for uncontrolled hypertension in
the general population, it is possible that the procedure is effective
in carefully selected patient populations characterized by high
sympathetic tone. Interestingly, studies have shown that in both
mice and humans with PKD, sympathetic tone is increased.5,6
Therefore, the idea that renal denervation may be an option in
the management of therapy-resistant hypertension in ADPKD
seems rational. Consistent with this hypothesis, several case re-
ports have suggested that renal denervation is effective for blood
pressure control in ADPKD.7-10
However, we should learn from the Symplicity trials. Evidence
from case reports and uncontrolled small-scale studies is not999
